Vita Life Sciences Ltd
ASX:VLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (3), the stock would be worth AU$2.39 (5% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.2 | AU$2.53 |
0%
|
| 3-Year Average | 3 | AU$2.39 |
-5%
|
| 5-Year Average | 3 | AU$2.39 |
-5%
|
| Industry Average | 18.8 | AU$15.02 |
+494%
|
| Country Average | 1.7 | AU$1.37 |
-46%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Vita Life Sciences Ltd
ASX:VLS
|
140.4m AUD | 3.2 | 13.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 9.4 | 44 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 3.4 | 26.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 2.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 1 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2 | 16.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.7 |
| 70th Percentile | 3.5 |
| Max | 3 073.7 |
Other Multiples
Vita Life Sciences Ltd
Glance View
Vita Life Sciences Ltd. engages in the formulation, packaging, sale and distribution of vitamins and supplements. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-08-23. The firm is involved in the formulating, packaging, sales and distributing vitamins and supplements. The Company’s core business is the development and distribution of over the counter (OTC) medicines, as well as complementary and alternative medicines, dietary supplements and health foods under various brand names throughout Australia, Malaysia, Singapore, Thailand, Vietnam, China and Indonesia. The company offers products under the brands, such as Herbs of Gold, VitaHealth, VitaScience and VitaLife. The firm operates in Australia, Singapore, Malaysia and others. The firm subsidiaries include Tetley Research Pty Limited, Tetley Treadmills Pty Limited, Tetley Manufacturing Pty Limited, Vimed Bio Sciences Pty Limited, Allrad No 19 Pty Limited, Lovin Pharma International Limited, Herbs of Gold Pty Limited, VitaHealth Laboratories Australia Pty Limited and Vita Institute of Health Pty Ltd.
